Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic steatohepatitis.

K S Kumar1, P F Malet

  • 1Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center at Dallas 75390-9151, USA.

Mayo Clinic Proceedings
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Double Beta Decays of ^{134}Xe with EXO-200 Phase II.

Physical review letters·2026
Same author

EMC Effect of Tritium and Helium-3 from the JLab MARATHON Experiment.

Physical review letters·2025
Same author

A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India.

American journal of epidemiology·2023
Same author

Precision Determination of the Neutral Weak Form Factor of ^{48}Ca.

Physical review letters·2022
Same author

New Measurements of the Beam-Normal Single Spin Asymmetry in Elastic Electron Scattering over a Range of Spin-0 Nuclei.

Physical review letters·2022
Same author

Measurement of the Nucleon F_{2}^{n}/F_{2}^{p} Structure Function Ratio by the Jefferson Lab MARATHON Tritium/Helium-3 Deep Inelastic Scattering Experiment.

Physical review letters·2022
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Nonalcoholic steatohepatitis (NASH) is an underrecognized liver disease causing elevated enzymes, often linked to obesity and diabetes. While typically benign, NASH can progress to cirrhosis, necessitating accurate diagnosis and defined therapies.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Nonalcoholic steatohepatitis (NASH) is an increasingly recognized liver condition.
  • It is characterized by liver histology similar to alcoholic hepatitis but without excessive alcohol use.
  • NASH affects a diverse population, including obese adults with metabolic syndrome, lean individuals, and children.

Purpose of the Study:

  • To highlight NASH as a common cause of elevated liver enzymes.
  • To describe the clinical characteristics and potential progression of NASH.
  • To review diagnostic standards and therapeutic options for NASH.

Main Methods:

  • Review of clinical presentation and diagnostic criteria for NASH.
  • Discussion of patient demographics, including age, weight, and comorbidities.

Related Experiment Videos

  • Consideration of liver biopsy as the gold standard for diagnosis.

    • Main Results:

    • NASH is frequently associated with obesity, diabetes, and hyperlipidemia.
    • The disease can occur in non-obese, healthy individuals and children.
    • While often benign, NASH may progress to advanced liver disease, including cirrhosis and portal hypertension.

    Conclusions:

    • Liver biopsy is essential for diagnosing NASH.
    • Therapeutic strategies for NASH are not well-established.
    • Weight reduction and ursodeoxycholic acid show potential benefits in managing NASH.